Skip to main content
Lifecare ASA logo

Lifecare ASA — Investor Relations & Filings

Ticker · LIFE ISIN · NO0013355859 LEI · 254900D88MYGZ7JD5P39 OL Manufacturing
Open in API
Filings indexed 812 across all filing types
Latest filing 2020-10-20 M&A Activity
Country NO Norway
Listing OL LIFE

About Lifecare ASA

https://lifecare.no/

Lifecare ASA is a clinical-stage medical sensor company specializing in the development of nanotechnology for medical applications. Its core activity involves creating miniaturized, implantable, and long-term nanobiosensors for the continuous monitoring of various body analytes. The company's primary focus is on developing a sensor for correct and continuous glucose monitoring to improve diabetes management. The business model is based on developing and licensing its proprietary sensor technology to facilitate the production and sale of advanced medical devices.

Recent filings

Filing Released Lang Actions
Vedr aksjebytte avtale Human Data - Evergreen 20.10.20
M&A Activity Classification · 99% confidence The document text describes an 'aksjebytte avtale' (share exchange agreement) involving Bionovate Technologies Corp., Evergreen Solutions Ltd., and Human Data AG, concerning shares in Digital Diagnostics AG. This transaction involves the exchange of shares and valuation, which falls under corporate actions related to mergers, acquisitions, or significant asset/share transfers. Since the document details a specific proposal or agreement related to a change in corporate structure or ownership interest, it aligns best with the M&A Activity category (TAR). It is not a standard regulatory report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Given the nature of the announcement regarding a significant transaction, TAR is the most appropriate classification.
2020-10-20 Norwegian
Lifecare - klargjøring vedr kjerneteknologi - 13.10.20
Regulatory Filings Classification · 95% confidence The document is titled "BØRSMELDING" (Stock Exchange Announcement) and is dated October 13, 2020. It addresses shareholder concerns following a stock price drop by providing updates on ongoing projects (FORGETDIABETES funding, delays in Digital Diagnostics AG's Covid-19 trials). This is a general, non-periodic announcement concerning operational and project status, not a formal financial report (like 10-K or IR), a dividend notice, or an earnings release. Since it is a regulatory announcement that doesn't fit the highly specific categories like DIRS, DIV, ER, or 10-K, the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2020-10-13 Norwegian
Lifecare - klargjøring vedr kjerneteknologi - 13.10.20
Fund Information / Factsheet Classification · 99% confidence The document provides a factual overview ('Fakta') of Lifecare AS, detailing its core business (medical device development, specifically the Sencell glucose monitoring technology), patent status, technical specifications (nanosensor technology, implantation), ongoing research projects (Forgetdiabetes, EU funding), and a joint venture (Digital Diagnostics AG) related to a COVID-19 rapid test. This content is characteristic of a company profile, factsheet, or general investor information document, rather than a formal regulatory filing (like 10-K, ER, or IR) or a specific announcement (like DIV or DIRS). Given the brief, summary nature focusing on key facts and technology, the most appropriate classification is Fund Information / Factsheet (FS). The document length (3572 chars) supports this being a summary rather than a comprehensive report.
2020-10-13 Norwegian
Lifecare - clearification regarding core technology 13.10.20
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company (Lifecare) dated October 13, 2020, addressing shareholder concerns following a stock price decrease. It clarifies the status of core technology, ongoing EU funding projects (FORGETDIABETES), and delays in clinical trials with a partner (Digital Diagnostics). This type of communication, which provides updates on operational matters, partnerships, and regulatory/project progress outside of standard periodic financial reports (like 10-K or IR), fits best under the general 'Regulatory Filings' category (RNS) as it is a market announcement clarifying material information, but does not fit the specific definitions for ER, CT, DIV, or DIRS. Given its nature as a general market clarification/update, RNS is the most appropriate fallback.
2020-10-13 English
Lifecare - klargjøring vedr kjerneteknologi - 13.10.20
Regulatory Filings Classification · 100% confidence The document is a short announcement from Lifecare addressing shareholder concerns following a drop in stock price. It clarifies that there are no changes to their core technology (Sencell) or partnerships, and provides updates on previously announced funding (FORGETDIABETES) and clinical trial delays (Cantisens/Covid-19). Since this is a direct communication clarifying operational status and addressing market concerns, and it is not a full financial report (10-K, IR), an earnings release (ER), or a formal proxy/voting document, it best fits the category of a general regulatory announcement or investor clarification. Given the context of addressing specific shareholder queries and providing operational updates outside of standard periodic filings, it aligns most closely with a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were more structured, but RNS serves as the best general catch-all for non-standard, material company news.
2020-10-13 Norwegian
Lifecare - clearification regarding core technology 13.10.20
Regulatory Filings Classification · 100% confidence The document is a short clarification issued by the company 'Lifecare' in response to a share price decrease, addressing shareholder questions about its core technology, ongoing projects (FORGETDIABETES), and partner updates (Digital Diagnostics/Cantisense Covid-19 test). It provides factual updates on ongoing business matters and technology status, rather than releasing formal periodic financial results (ER/IR), announcing a major corporate event (AGM/TAR), or detailing executive pay (DEF 14A). Since it is a specific, non-standard announcement clarifying business operations and addressing market concerns, and it doesn't fit the definitions for DIRS, DIV, CAP, or LTR, it best fits the general 'Regulatory Filings' category as a miscellaneous regulatory disclosure or market clarification, which aligns with the RNS definition for general regulatory announcements that don't fit elsewhere.
2020-10-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.